Citi added a “90-day negative catalyst watch” on shares of Tandem Diabetes while keeping a Buy rating on the name with a $57 price target heading into the Q3 report. Citi’s latest diabetes survey suggests flat Tandem share of new patient starts in the U.S. in Q3, the analyst tells investors in a research note. The firm says that while the share of Mobi being prescribed is anticipated to increase, this appears to be coming at the expense of t:slim volume, hence the stable share. The firm thinks a meaningful beat to earnings will now be harder to achieve.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- App data suggests potential Q3 shipment beat from Tandem, says Morgan Stanley
- TJX downgraded, Crocs upgraded: Wall Street’s top analyst calls
- Tandem Diabetes initiated with an Equal Weight at Morgan Stanley
- Street analysts say diabetes stocks “overreacting” to Lilly GLP-1 study results
- Diabetes stock selloff on Lilly Surmount-1 results overdone, says Citi